VolitionRx Closes $8.7 Million Confidentially-Marketed Public Offering

Stradling client VolitionRx Limited announced the closing of a confidentially-marked underwritten public offering of common stock. The gross proceeds to Volition from the offering, before deducting underwriting commissions and other offering expenses payable by Volition, were approximately $8.7 million. Newbridge Securities Corporation acted as the sole book-running manager of the offering.

Volition is a multi-national epigenetics company powered by Nu.Q®, its proprietary nucleosome quantification platform. Through its subsidiaries, Volition is developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19.